Patents Assigned to Merck
  • Stable (CF3)2N— salts and process for preparing them
    Patent number: 6582849
    Abstract: The invention relates to stable (CF3)2N− salts, to a process for preparing them and to their use as precursor for organic compounds.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: June 24, 2003
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Udo Heider, Michael Schmidt, Peter Sartori, Nikolai Ignatev, Adrji Kucherna
  • Adsorption power for removing mercury from high temperature high moisture gas streams
    Patent number: 6582497
    Abstract: There is disclosed an adsorption powder effective for capturing mercury from a high temperature, high moisture gas stream comprising: about 1-97% carbon; about 1-97% of alkaline material; about 1-97% cupric chloride impregnated carbon, and about 1-60% carbon impregnated with KI3. Additionally, a method of removing mercury from high temperature, high moisture gas streams, using the adsorption powder of the invention, is disclosed.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: June 24, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Rudy J. Maes, Youssef El-Shoubary, Subash Seth
  • Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
    Patent number: 6583126
    Abstract: The invention encompasses the novel class of compounds represented by formula I which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
    Type: Grant
    Filed: December 21, 2000
    Date of Patent: June 24, 2003
    Assignee: Merck Erosst Canada & Co.
    Inventors: Yves Leblanc, Claude Dufresne, Scheigetz John, Cheuk Kun Lau, Chun Sing Li, Patrick Roy, Michael Boyd, Zhaoyin Wang
  • Electro-optical liquid crystal display
    Patent number: 6582782
    Abstract: The invention relates to an electro-optical liquid-crystal display having a realignment layer for realignment of the liquid crystals whose field has a component, which is crucial for the realignment, parallel to the liquid-crystal layer, containing a liquid-crystalline medium of positive dielectric anisotropy, where the medium comprises at least one mesogenic compound of the formula I: in which R1 and L are defined herein.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: June 24, 2003
    Assignee: Merck Patent Gesellschaft
    Inventors: Michael Heckmeier, Brigitte Schuler, Achim Goetz, Matthias Bremer
  • Process for the preparation of ss-mannitol for direct compression
    Publication number: 20030114717
    Abstract: The present invention relates to a process for the preparation of mannitol for direct compression having a content of the &bgr;-modification of greater than 90%.
    Type: Application
    Filed: December 12, 2002
    Publication date: June 19, 2003
    Applicant: Merck Patent GmbH
    Inventors: Martin Erdmann, Walter Hamm
  • Substituted isonipecotyl derivatives as inhibitors of cell adhesion
    Patent number: 6579889
    Abstract: Compounds of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: June 17, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Stephen E. de Laszlo, Clare E. Gutteridge, William K. Hagmann
  • Interference pigments
    Patent number: 6579355
    Abstract: The present invention relates to an interference pigment based on multiply-coated platelet-shaped substrates, comprising at least one layer sequence of (A) a high refractive index coating comprising a mixture of TiO2 and Fe2O3 in a ratio of about 10:1 to about 3:1 and optionally one or more metal oxides in amounts of ≲ about 20% by weight based on the layer (A), (B) a colorless coating having a refractive index n ≲ about 1.8, and optionally (C) an outer protective layer.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: June 17, 2003
    Assignee: Merck Patent Gesellschaft mit Beschraenkter Haftung
    Inventors: Christoph Schmidt, Klaus Bernhardt, Dieter Heinz
  • Prolines as antimicrobial agents
    Patent number: 6579894
    Abstract: Transfer ribonucleic acid (tRNA) synthetase inhibitors, salts, and pharmaceutically acceptable compositions thereof of the general formula: wherein Ar is aryl and heteroaryl; L is —C(O)N(Q)CH2—, or —CR10R11OCR12R13—; Q is hydrido, —(CH2)mCO2H and —(CH2)mCO2CH3, m is 1, 2, 3, and 4; R1, R2, R9, R10, R11, R12 and R13 are hydrido or lower alkyl; wherein Het is a heterocyclic moiety, the inhibitors are suitable for use as antimicrobial agents.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: June 17, 2003
    Assignees: Merck & Co., Inc., Cubist Pharmaceuticals, Inc.
    Inventors: Milton L. Hammond, Aaron H. Leeman, Milana Maletic, Gina M. Santorelli, Sherman T. Waddell, John Finn, Michael Morytko, Siya Ram, Dennis Keith
  • Triazolo-pyridazine derivatives as ligands for GABA receptors
    Patent number: 6579875
    Abstract: 1,2,4-triazolo[4,3-b]pyridazine derivatives, possessing a fluoro-substituted phenyl ring at the 3-position and a heteroaryl-alkoxy moiety at the 6-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, are useful in the treatment of anxiety and convulsions.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: June 17, 2003
    Assignee: Merck Sharp & Dohme Limited
    Inventors: William Robert Carling, Jose Luis Castro Pineiro, Ian James Collins, Alexander Richard Guiblin, Timothy Harrison, Andrew Madin, Kevin William Moore, Michael Geoffrey Russell, Gayle Scott, Leslie Joseph Street
  • Use of an angiotensin II receptor antagonist for the preparation of drugs to increase the survival rate of renal transplant patients
    Patent number: 6576652
    Abstract: The present invention relates to the use, for the preparation of drugs to increase the survival rate of transplant patients, including renal and heart transplant patients, of a therapeutically effective amount of an angiotension II receptor antagonist compound, such as the class of substituted imidazoles represented by formula (I) and in particular by losartan potassium, 2-butyl-4-chloro-[(2′-tetrazol-5-yl)biphenyl-4-il]methyl]-5-(hydroxymethyl)imidazole potassium salt.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: June 10, 2003
    Assignee: Merck Sharp & Dohme (Italia) S.p.A.
    Inventor: Giuseppe Remuzzi
  • &bgr;-alanine derivatives
    Patent number: 6576637
    Abstract: The invention relates to &bgr;-alanine derivatives of formula (I), wherein Q1, Q2, Q3, Q4, R1, R2, R3, R4, R5, R6 and n have the meaning as disclosed in the disclosure, and to their physiologically acceptable salts or solvates. Said substances are integrin inhibitors and can be used in the treatment of thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections and restenosis after angioplasty or in pathological processes induced or propagated by angiogenesis.
    Type: Grant
    Filed: August 20, 2001
    Date of Patent: June 10, 2003
    Assignee: Merck Patent GmbH
    Inventors: Günter Hölzemann, Simon Goodmann, Alfred Jonczyk, Wolfgang Stähle
  • Probe wash vessel having removable inner cannula
    Patent number: 6575181
    Abstract: A probe wash vessel characterized as having a cylindrical-shaped, outer test tube with at least two vertically aligned faucets, and an inner cannula positioned within the test tube, wherein the inner cannula is characterized by a top funnel opening attached to a stem, the stem characterized as having two arm extensions are attached to the two faucets, wherein washing fluid influent and effluent through the arm extensions washes a probe inserted through the top funnel into the stem.
    Type: Grant
    Filed: October 24, 2000
    Date of Patent: June 10, 2003
    Assignee: Merck & Co., Inc.
    Inventor: Gregory A. Wimmer
  • TN and STN liquid-crystal displays
    Publication number: 20030104143
    Abstract: The invention relates to TN and STN liquid-crystal displays and to the novel nematic liquid-crystal mixtures used therein, characterized in that they comprise one or more compounds of the formula I 1
    Type: Application
    Filed: June 27, 2002
    Publication date: June 5, 2003
    Applicant: Merck Patent GmbH
    Inventor: Juliane Suermann
  • DNA molecules encoding human nuclear receptor protein nNR7-1
    Publication number: 20030104531
    Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding a novel member to the human nuclear receptor superfamiliy, designated nNR7 and/or nNR7-1. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of nNR7 and/or nNR7-1 activity, and production of antibodies against nNR7 and/or nNR7-1, or epitopes thereof.
    Type: Application
    Filed: March 4, 2002
    Publication date: June 5, 2003
    Applicant: Merck & co., Inc.
    Inventor: Fang Chen
  • Anisotrpic polymer film
    Publication number: 20030104144
    Abstract: An anisotropic polymer film comprising a polymerised chiral liquid crystal material with helically twisted structure and having areas with different helical twist sense is useful for decorative or security applications.
    Type: Application
    Filed: September 24, 2002
    Publication date: June 5, 2003
    Applicant: Merck Patent GmbH
    Inventors: Robert Hammond-Smith, John Patrick, Alison Linda May
  • Doped positive-electrode material in electrochemical cells
    Patent number: 6573005
    Abstract: An electrode having a positive-electrode material. The positive electrode material is a tin oxide doped with F, Cl, Br, I, S, Se, Te, B, N or P anions.
    Type: Grant
    Filed: May 25, 2001
    Date of Patent: June 3, 2003
    Assignee: Merck Patentgesellschaft
    Inventors: Lilia Heider, Natascha Lotz, Tanja Sandner, Mathias Rothenburger, Anja Amann
  • Method for producing L-ascorbic acid
    Patent number: 6573393
    Abstract: The invention relates to a method for producing L-ascorbic acid from 2-keto-L-gulonic acid or 2,3-4,6-diacetone-2-keto-L-gulonic acid. The reaction is carried out in the presence of water and hydrogen halide and the concentration of the hydrogen halide in water is greater than 37 wt. %.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: June 3, 2003
    Assignee: Merck KGAA
    Inventors: Ulrich Fechtel, Wolfgang Heinz, Klaus Beschmann, Bernd Müller, Jöran Stoldt
  • Purification of battery electrolytes by means of chemical adsorption
    Patent number: 6573002
    Abstract: The present invention relates to the removal of protic impurities from battery electrolytes which are suitable for lithium cells by chemical adsorption.
    Type: Grant
    Filed: February 23, 2001
    Date of Patent: June 3, 2003
    Assignee: Merck Patent GmbH
    Inventors: Michael Jungnitz, Holger Wiederhold
  • DNA molecules encoding the melanocortin 4 receptor protein from rhesus monkey
    Patent number: 6573070
    Abstract: The present invention relates to rhesus monkey DNA molecules encoding the melanocortin-4 receptor protein, recombinant vectors comprising DNA molecules encoding rhesus MC-4R, recombinant host cells which contain a recombinant vectors encoding rhesus MC-4R, the rhesus MC-4R protein encoded by the DNA molecule, and methods of identifying selective agonists and antagonists of rhesus MC-4R.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: June 3, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Douglas J. MacNeil, David H. Weinberg, Leonardus H. T. Van Der Ploeg
  • Method for producing ortho-alkylated benzoic acid derivatives
    Patent number: 6573404
    Abstract: The invention relates to a process for the preparation of ortho-alkylated benzoic acid derivatives of the formula I characterized in that an aryl bromide of the formula II is reacted with a secondary or tertiary organolithium compound and CO2.
    Type: Grant
    Filed: October 8, 2002
    Date of Patent: June 3, 2003
    Assignee: Merck Patent GmbH
    Inventors: Ekkehard Bartmann, Ingeborg Stein